A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
نویسندگان
چکیده
Objectives The primary objective is to assess the safely of combining Ipilimumab with palliative radiation therapy in patients with unresectable Stage IV melanoma. Secondary objectives include assessment of 1) induction of anti-melanoma immune responses using laboratory correlative studies of immune responses to melanoma antigens, 2) comparison of tumor response rates and duration of response at unirradiated tumor sites in patients with Stage IV disease with historically stage IV patients treated with Ipilimumab alone.
منابع مشابه
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.
Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records of patients treated with ipilimumab and radiotherapy for melanoma at our insti...
متن کاملMetastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After com...
متن کاملEffects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
Introduction Adoptive cell therapy, where patients are treated with expanded autologous T cells derived from tumor specimens, is currently one of the most effective treatments for stage IV malignant melanoma. Clinical studies have indicated a link between treatment with anti-CTLA-4 treatment (e.g. Ipilimumab) prior to tumor removal, and a favorable treatment response to subsequent adoptive cell...
متن کاملHealth related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
BACKGROUND In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial's 12 week treatment induction period. METHODS The Phase III c...
متن کاملBilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
BACKGROUND This report presents a novel case of bilateral neuroretinitis and anterior uveitis in a patient receiving ipilimumab treatment for metastatic cutaneous melanoma and summarizes the literature regarding treatment options for patients with ipilimumab-related ocular immune-related adverse events. FINDINGS The medical chart was reviewed, a literature search was performed, and the result...
متن کامل